BCAB Key Statistics, Chart & Performance
The current stock price of BCAB is 0.5677 USD. In the past month the price decreased by -27.16%. In the past year, price decreased by -16.27%.
BCAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About BCAB
Company Profile
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Company Info
BIOATLA INC
11085 Torreyana Road
San Diego CALIFORNIA 92121 US
CEO: Jay M. Short
Employees: 61
Phone: 18585580708
BIOATLA INC / BCAB FAQ
What does BIOATLA INC do?
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
What is the current price of BCAB stock?
The current stock price of BCAB is 0.5677 USD. The price decreased by -20.82% in the last trading session.
What is the dividend status of BIOATLA INC?
BCAB does not pay a dividend.
How is the ChartMill rating for BIOATLA INC?
BCAB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the market cap for BIOATLA INC?
BIOATLA INC (BCAB) has a market capitalization of 33.38M USD. This makes BCAB a Nano Cap stock.
When does BIOATLA INC (BCAB) report earnings?
BIOATLA INC (BCAB) will report earnings on 2026-03-25, after the market close.
Can you provide the short interest for BCAB stock?
The outstanding short interest for BIOATLA INC (BCAB) is 8.3% of its float.
BCAB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCAB. When comparing the yearly performance of all stocks, BCAB is a bad performer in the overall market: 81.23% of all stocks are doing better.
BCAB Financial Highlights
Over the last trailing twelve months BCAB reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS increased by 32.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -438.62% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCAB Forecast & Estimates
7 analysts have analysed BCAB and the average price target is 10.2 USD. This implies a price increase of 1696.72% is expected in the next year compared to the current price of 0.5677.
For the next year, analysts expect an EPS growth of 23.5% and a revenue growth -100% for BCAB